ImmunityBio, Inc. Common Stock (IBRX)
ImmunityBio, Inc. (IBRX) is a biotechnology company focused on developing innovative immunotherapies and cancer treatments. The company specializes in next-generation immuno-oncology, aiming to enhance the body's immune response to fight cancer and infectious diseases through its proprietary platform technologies.
Company News
The article highlights three biotech stocks with significant potential growth: Viking Therapeutics, ImmunityBio, and Maze Therapeutics, each showing promising clinical trial results and analyst optimism despite current market volatility.
The cancer immunotherapy market is projected to reach $258.22 billion by 2031, driven by breakthrough treatments and FDA fast-track approvals. Multiple companies are developing innovative immunotherapies targeting various cancer types with promising clinical trial results.
HCW Biologics reported financial results for Q2 2024, including a net loss of $15.3 million. The company reached a settlement agreement to resolve an arbitration case, and is pursuing a financing plan including an equity offering and out-licensing of non-core assets.
ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.
Last month's big winners were tricky to handle due to the amount of speculation investors were willing to do with them.